German and Korean Firm Join Hands to Discover Cancer Drugs

Thursday, June 4, 2015

Source: BioSpectrum

Germany's translational drug discovery organization, Lead Discovery Center (LDC), has entered into a licence deal with Korea's Qurient for exclusive worldwide rights to a series of highly-selective CDK7 inhibitors discovered at the LDC for the treatment of cancer, inflammation and viral infections. Qurient, started in 2009 as a venture capital funded spin-off biotechnology company of the Institut Pasteur Korea (IPK), is engaged in innovative sciences and clinical development.

View All News »